category,datetime,headline,id,image,related,source,summary,url
company,1769383800,FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review,138256815,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BIIB,Yahoo,"If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA action date set for May 24, 2026 TOKYO and CAMBRIDGE, Mass., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that",https://finnhub.io/api/news?id=fbd8784ccaa765543bcd9ac77ab70d91e5fb1fed45df695745ea867cbc4fb147
company,1769383800,FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review,138256814,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BIIB,Yahoo,"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, ""Biogen"") announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's Supplemental Biologics License Application (sBLA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose. LEQEMBI is indicated for the treatment of",https://finnhub.io/api/news?id=26947a5dffd35c4f6dbf89d5e0980b80c096853c46889e82d705dcc8d011e138
